Summary of Significant Accounting Policies - Additional Information (Details)							1 Months Ended			12 Months Ended
	Nov. 11, 2022	Sep. 30, 2022	Jun. 22, 2022 $ / shares	Jun. 01, 2022 USD ($) shares	Dec. 24, 2019	Oct. 01, 2017 USD ($)	Jan. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Nov. 30, 2021 USD ($)	Dec. 31, 2022 USD ($) Customer Segment shares	Dec. 31, 2021 USD ($) Segment shares	Dec. 31, 2020 USD ($) shares	Mar. 13, 2023 USD ($)	Sep. 30, 2020 shares	Sep. 17, 2020 shares	Dec. 31, 2019 shares
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split, description												1-for-6 reverse stock split
Stockholders' equity note, stock split, conversion ratio												0.167
Common stock, Authorized shares | shares										61,666,666	61,666,666	61,666,666			61,666,666	13,333,333
Restricted Cash
Investments										$ 0	$ 0
Other Comprehensive Income (Loss)
Foreign currency translation adjustment, Tax										0	0
Foreign currency translation adjustment										1,645,000	1,786,000
Property and Equipment
Impairment Charges										0
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Liability related to sale of future royalties										0
Credit received as reduction to payroll tax expense										0	4,200,000
Contract Liabilities										6,100,000	5,900,000
Contract Assets										0	0
Revenues										118,566,000	129,071,000
Operating expenses										153,906,000	208,109,000
Interest income										$ 1,909,000	5,000
Allowance for Cash Discounts
Time period needed typically to settle cash discounts										34 days
Allowance for cash discounts										$ 1,800,000	2,000,000.0
Reserve for allowance for cash discounts										400,000	800,000
Allowance for Doubtful Accounts
Allowance for doubtful accounts, write-offs										100,000	200,000
Allowance related to chargebacks										3,400,000	1,000,000.0
Payment related to chargebacks										3,200,000	$ 1,500,000
Reserve for chargebacks allowance										$ 300,000
Segment and Geographic Information
Number of operating segments | Segment										1	1
Number of reportable operating segments | Segment										1	1
Cash, cash equivalents, and restricted cash										$ 44,675,000	$ 65,223,000	$ 102,895,000
Cash paid for interest										7,157,000	6,000
Net loss										(65,916,000)	(103,954,000)
Royalty Revenues
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Revenues										$ 14,221,000	14,882,000
Product revenue
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Number of customers | Customer										5
Accounts receivable
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Number of customers | Customer										4
Convertible Senior Secured Notes due 2024
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split, description										1-for-6
Segment and Geographic Information
Interest rate (as a percent)					6.00%											6.00%
Debt repurchase price percentage on principal amount					100.00%
VERSION A
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Reverse stock split, description	1-for-2 to 1-for-20
Segment and Geographic Information
Cash, cash equivalents, and restricted cash										$ 44,700,000
Restricted cash										6,200,000
Periodic Interest payment from restricted escrow cash										6,200,000
Licensing royalties received								$ 16,500,000
Closing bid price of common stock | $ / shares			$ 1.00
Number of additional days for complying with minimum bid requirement			180 days
Net loss										$ (65,900,000)	$ (104,000,000.0)
VERSION A | Convertible Senior Secured Notes due 2024
Segment and Geographic Information
Interest rate (as a percent)										6.00%
Number of shares issued | shares				10,992,206
Cash paid for interest				$ 900,000
Periodic Interest payment from restricted escrow cash										$ 6,200,000
Esteve Germany [Member]
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Upfront Payment Received									$ 5,900,000
Esteve Pharmaceuticals
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Revenues										2,900,000
Revenue from remaining performance obligation										700,000
Alkermes
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Litigation Settlement, Amount Awarded from Other Party								18,300,000
Operating expenses								16,600,000
Interest income								1,700,000
Alkermes | Subsequent event
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Litigation Settlement, Amount Awarded from Other Party							$ 18,300,000
Alkermes | Supply agreement
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Litigation Settlement, Amount Awarded from Other Party								$ 18,300,000
Alkermes | VERSION A
Segment and Geographic Information
Licensing royalties received										$ 1,800,000
Silicon Valley Bank
Segment and Geographic Information
Percentage of unrestricted cash and cash equivalents										22.00%
Silicon Valley Bank | Subsequent event
Segment and Geographic Information
Deposit													$ 8,300,000
Royalty Agreement
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Non cash royalty payment received						$ 40,000,000
Estimated effective annual interest rate										15.00%
Neurelis Collaboration Agreement | Royalty Revenues
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Revenues										$ 3,800,000
Royalty revenue capped										$ 5,100,000
Minimum
Property and Equipment
Estimated useful lives										1 year
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Product revenue payment term										30 days
Minimum | Supply agreement | Alkermes License Agreement
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Purchase requirements threshold percentage		75.00%
Maximum
Property and Equipment
Estimated useful lives										7 years
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Product revenue payment term										35 days
Maximum | Supply agreement | Alkermes License Agreement
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Purchase requirements threshold percentage		100.00%
Maximum | Supply agreement | Patheon Inc Second Manufacturing agreement
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Purchase requirements threshold percentage		25.00%
UNITED STATES | Customers | Product revenue
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Concentration risk, percentage										91.00%	91.00%
UNITED STATES | Customers | Accounts receivable
Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
Concentration risk, percentage										85.00%	92.00%
Letters of Credit
Restricted Cash
Restricted Cash and Cash Equivalents										$ 300,000
Previously Reported
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Common stock, Authorized shares | shares												370,000,000		370,000,000		80,000,000